Cerca
Menu
Foto del docente

Andrea Rubboli

Professore a contratto a titolo gratuito

Dipartimento di Scienze Biomediche e Neuromotorie

Pubblicazioni

  1. Management of patients treated with oral anticoagulant therapy undergoing percutaneous coronary intervention with stent implantation: the PERSEO Registry. Sciahbasi A, De Rosa S, Gargiulo G, Giacoppo D, Calabrò P, Talarico GP, Zilio F, Talanas G, Tebaldi M, Andò G, Rigattieri S, Misuraca L, Cortese B, Musuraca G, Lucci V, Guiducci V, Renda G, Zezza L, Versaci F, Giannico MB, Caruso M, Fischetti D, Colletta M, Santarelli A, Larosa C, Iannone A, Esposito G, Tarantini G, Musumeci G, Rubboli A. J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001607
  2. Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial. Verburg A, Bor WL, Küçük IT, Henriques JPS, Vink MA, Ruifrok WT, Plomp J, Heestermans TACM, Schotborgh CE, Vlaar PJ, Magro M, Rikken SAOF, van den Broek WWA, van Mieghem CAG, Cornelis K, Rosseel L, Dujardin KS, Vandeloo B, Vandendriessche T, Ferdinande B, van 't Hof AWJ, Tijssen JGP, Limbruno U, De Caterina R, Rubboli A, Angiolillo DJ, Adriaenssens T, Dewilde W, Ten Berg JM. EuroIntervention. 2024 Jul 15;20(14):e898-e904. doi: 10.4244/EIJ-D-24-00100.
  3. Atrial Fibrillation, Atrial Myopathy, and Thromboembolism: The Additive Value of Echocardiography and Possible New Horizons for Risk Stratification. Campora A, Lisi M, Pastore MC, Mandoli GE, Ferrari Chen YF, Pasquini A, Rubboli A, Henein MY, Cameli M. J Clin Med. 2024 Jul 4;13(13):3921. doi: 10.3390/jcm13133921.
  4. Inpatient Cardiac Rehabilitation Following Heart Valve Surgey: A Setting for the Tailored Management of Antithrombotic Therapy. Morici N, Di Lauro S, Cusmano I, Birocchi S, Torracca L, Rubboli A. Eur J Prev Cardiol. 2024 Apr 29:zwae154. doi: 10.1093/eurjpc/zwae154.  
  5. A COVID-19 specific multiparametric and ECG-based score for the prediction of in-hospital mortality: ELCOVID score. Zuin M, Ferrari R, Guardigli G, Malagù M, Vitali F, Zucchetti O, D'Aniello E, Di Ienno L, Gibiino F, Cimaglia P, Grosseto D, Corzani A, Galvani M, Ortolani P, Rubboli A, Tortorici G, Casella G, Sassone B, Navazio A, Rossi L, Aschieri D, Mezzanotte R, Manfrini M, Bertini M. Intern Emerg Med. 2024 Apr 23. doi: 10.1007/s11739-024-03599-3.
  6. De-escalation of antithrombotic treatment after acute coronary syndrome, a new paradigm. Rubboli A, Atar D, Sibbing D. Intern Emerg Med. 2024 Apr 10. doi: 10.1007/s11739-024-03590-y.
  7. [Antithrombotic therapy after surgical mitral valve repair: review of the evidence and updated proposals]. Rubboli A, Fiorentino MF, Lisi M, Arioti M, Galvani M, Savini C. G Ital Cardiol (Rome). 2024 Mar;25(3):157-161. doi: 10.1714/4209.42001.
  8. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, Cerrato E, Sacchetta G, Jurado-Roman A, Menozzi A, Amat Santos I, Díez Gil JL, Ruozzi M, Barbierato M, Fileti L, Picchi A, Lodolini V, Biondi-Zoccai G, Maietti E, Pavasini R, Cimaglia P, Tumscitz C, Erriquez A, Penzo C, Colaiori I, Pignatelli G, Casella G, Iannopollo G, Menozzi M, Varbella F, Caretta G, Dudek D, Barbato E, Tebaldi M, Campo G; FIRE Trial Investigators. N Engl J Med. 2023 Sep 7;389(10):889-898. doi: 10.1056/NEJMoa2300468.
  9. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. Gorog DA, Ferreiro JL, Ahrens I, Ako J, Geisler T, Halvorsen S, Huber K, Jeong YH, Navarese EP, Rubboli A, Sibbing D, Siller-Matula JM, Storey RF, Tan JWC, Ten Berg JM, Valgimigli M, Vandenbriele C, Lip GYH. Nat Rev Cardiol. 2023 Dec;20(12):830-844. doi: 10.1038/s41569-023-00901-2. Epub 2023 Jul 20.
  10. The European Society of Cardiology Working Group on Thrombosis. Rubboli A, Gorog DA, Vilahur G. Eur Heart J. 2023 Jul 1;44(25):2270-2271. doi: 10.1093/eurheartj/ehad063.
  11. Incidence and mortality of infective endocarditis in the last decade: a single center study. Lisi M, Flamigni F, Russo M, Cameli M, Mandoli GE, Pastore MC, Mele D, Campo G, Henein MY, Rubboli A. J Cardiovasc Med (Hagerstown). 2023 Feb 1;24(2):105-112. doi: 10.2459/JCM.0000000000001410.
  12. Left Atrial Remodeling in Response to Aortic Valve Replacement: Pathophysiology and Myocardial Strain Analysis. Lisi M, Pastore MC, Fiorio A, Cameli M, Mandoli GE, Righini FM, Cavigli L, D'Ascenzi F, Focardi M, Rubboli A, Campo G, Mondillo S, Henein MY. Life (Basel). 2022 Dec 10;12(12):2074. doi: 10.3390/life12122074.
  13. Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis. Andreotti F, Geisler T, Collet JP, Gigante B, Gorog DA, Halvorsen S, Lip GYH, Morais J, Navarese EP, Patrono C, Rocca B, Rubboli A, Sibbing D, Storey RF, Verheugt FWA, Vilahur G. Eur Heart J. 2023 Jan 21;44(4):262-279. doi: 10.1093/eurheartj/ehac515.
  14. Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology. Patti G, Cavallari I, Cesaro A, Gragnano F, Riva L, Fimiani F, Cuccia C, Fresco C, Calabrò P, Leonardi S, Marcucci R, Rubboli A. Vascul Pharmacol. 2023 Feb;148:107137. doi: 10.1016/j.vph.2022.107137.
  15. Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent. Sciahbasi A, Gargiulo G, Talarico GP, Cesaro A, Zilio F, De Rosa S, Talanas G, Tebaldi M, Andò G, Rigattieri S, Misuraca L, Cortese B, Imperadore F, Lucci V, Guiducci V, Renda G, Zezza L, Versaci F, Giannico MB, Caruso M, Spaccarotella C, Calabrò P, Esposito G, Tarantini G, Musumeci G, Rubboli A. J Cardiovasc Med (Hagerstown). 2022 Nov 1;23(11):738-743. doi: 10.2459/JCM.0000000000001372.
  16. Left atrial myocardial intrinsic function remodeling response to repair of primary mitral regurgitation. Lisi M, Cameli M, Mandoli GE, Pastore MC, Righini FM, Flamigni F, D'Ascenzi F, Cavigli L, Focardi M, Rubboli A, Campo G, Mondillo S, Henein MY. Echocardiography. 2022 Oct;39(10):1264-1268. doi: 10.1111/echo.15452.
  17. [Screening for atrial fibrillation in the general population: experience from a cardiovascular risk campaign in the Emilia-Romagna Region]. Di Pasquale G, Cardelli LS, Canovi L, Dal Passo B, Frascaro F, Zanarelli L, Guardigli G, Campo G, Aschieri D, Vignali L, Navazio A, Rubboli A, Ortolani P, Galvani M, Ni M, Piovaccari G, Tortorici G, Urbinati S, Tondi S, Sassone B, Tortorella G, De Palma R, Casella G, Boriani G. G Ital Cardiol (Rome). 2022 Sep;23(9):703-709. doi: 10.1714/3860.38453.
  18. Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus.Di Mario C, Genovese S, Lanza GA, Mannucci E, Marenzi G, Sciatti E, Pitocco D; Expert Panel Group. Cardiovasc Diabetol. 2022 Aug 27;21(1):164. doi: 10.1186/s12933-022-01598-2.
  19. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH. Thromb Haemost. 2022 Oct;122(10):1625-1652. doi: 10.1055/s-0042-1750385.
  20. ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. De Luca L, Rubboli A, Lettino M, Tubaro M, Leonardi S, Casella G, Valente S, Rossini R, Sciahbasi A, Natale E, Trambaiolo P, Navazio A, Cipriani M, Corda M, De Nardo A, Francese GM, Napoletano C, Tizzani E, Nardi F, Roncon L, Caldarola P, Riccio C, Gabrielli D, Oliva F, Massimo Gulizia M, Colivicchi F. Eur Heart J Suppl. 2022 May 18;24(Suppl C):C254-C271. doi: 10.1093/eurheartj/suac020.
  21. [ANMCO Position paper: Antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes]. De Luca L, Rubboli A, Lettino M, Tubaro M, Leonardi S, Casella G, Valente S, Rossini R, Sciahbasi A, Natale E, Trambaiolo P, Navazio A, Cipriani M, Corda M, De Nardo A, Francese GM, Napoletano C, Tizzani E, Roncon L, Caldarola P, Riccio C, Gabrielli D, Oliva F, Gulizia MM, Colivicchi F. G Ital Cardiol (Rome). 2022 May;23(5):379-395. doi: 10.1714/3796.37818.
  22. In-hospital antithrombotic therapy and outcomes of elderly patients on warfarin undergoing percutaneous coronary intervention: Insights from the WAR-STENT registry. Zagnoni S, Campo G, Sciahbasi A, Rubboli A. Indian Heart J. 2022 May-Jun;74(3):256-257. doi: 10.1016/j.ihj.2022.04.011.
  23. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH. Europace. 2022 Nov 22;24(11):1844-1871. doi: 10.1093/europace/euac020.
  24. Detection of myocardial fibrosis by speckle-tracking echocardiography: from prediction to clinical applications. Lisi M, Cameli M, Mandoli GE, Pastore MC, Righini FM, D'Ascenzi F, Focardi M, Rubboli A, Mondillo S, Henein MY. Heart Fail Rev. 2022 Sep;27(5):1857-1867. doi: 10.1007/s10741-022-10214-0. E
  25. Rare Causes of Acute Coronary Syndrome: The JAK2 V617F Mutation-Positive Myeloproliferative Neoplasms: A Cardio-Hematological Perspective. Cantoni S, Colombo C, Soriano F, Oreglia JA, Sacco A, Veronese S, Brunelli D, Rubboli A, Morici N. Thromb Haemost. 2022 Aug;122(8):1429-1431. doi: 10.1055/a-1742-0361.
  26. Could the PARIS Risk Scores Be Useful for the Choice of Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention? De Luca L, Bolognese L, Rubboli A, Lucci D, Gabrielli D, Colivicchi F, Gulizia MM; MATADOR-PCI Investigators. Cardiology. 2022;147(2):133-136. doi: 10.1159/000521673.
  27. Appropriate dosing of the individual direct oral anticoagulants in atrial fibrillation: Differences in the questions to be answered. Rubboli A, Morici N, Lip GYH. Eur J Intern Med. 2022 May;99:116-117. doi: 10.1016/j.ejim.2022.01.014.
  28. [Changes in cardiac implantable electronic device follow-up induced by the COVID-19 pandemic in 2020: report of a single-centre experience]. Argnani MS, Tomasi C, Amatulli N, Calderoni L, Castellini A, Dal Monte A, Drudi D, Fabbri L, Gianelli M, Giannotti F, Rigon M, Rubino I, Smarrazzo V, Rubboli A. G Ital Cardiol (Rome). 2022 Jan;23(1):4-9. doi: 10.1714/3715.37054.
  29. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. Battistoni I, Francioni M, Morici N, Rubboli A, Podda GM, Pappalardo A, Abdelrahim MEA, Elgendy MO, Elgendy SO, Khalaf AM, Hamied AAM, Garcés HH, Abdelhamid OES, Tawfik KAM, Zeduri A, Bassi G, Pongetti G, Angelini L, Giovinazzo S, Garcia PM, Serino FS, Polistina GE, Fiorentino G, Barbati G, Toniolo A, Fabbrizioli A, Belenguer-Muncharaz A, Porto I, Ocak S, Minuz P, Bernal F, Hermosilla I, Borovac JA. J Cardiovasc Med (Hagerstown). 2022 Apr 1;23(4):264-271. doi: 10.2459/JCM.0000000000001284.
  30. Left atrial appendage thrombosis in a patient with Friedreich Ataxia-related cardiomyopathy, left ventricular systolic dysfunction, and atrial fibrillation. Russo M, Nuzzo A, Foschi M, Boarin S, Lorenzetti S, Tomasi C, Querzani P, Rubboli A. SAGE Open Med Case Rep. 2021 Oct 30;9:2050313X211056419. doi: 10.1177/2050313X211056419.
  31. Pericarditis following acute coronary syndrome: epidemiology and treatment. Tavecchia GA, Martini C, Rubboli A, Brucato A, Morici N. Intern Emerg Med. 2022 Jan;17(1):275-277. doi: 10.1007/s11739-021-02854-1.
  32. In- and out-of-hospital mortality for myocardial infarction during the first wave of the COVID-19 pandemic in Emilia-Romagna, Italy: A population-based observational study. Campo G, Fortuna D, Berti E, De Palma R, Pasquale GD, Galvani M, Navazio A, Piovaccari G, Rubboli A, Guardigli G, Galiè N, Boriani G, Tondi S, Ardissino D, Piepoli M, Banchelli F, Santarelli A, Casella G; AMI-Co investigators. Lancet Reg Health Eur. 2021 Mar 2;3:100055. doi: 10.1016/j.lanepe.2021.100055.
  33. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group. Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.
  34. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group. Eur J Cardiothorac Surg. 2021 Oct 22;60(4):727-800. doi: 10.1093/ejcts/ezab389.
  35. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, Sánchez PL, Anguita M, Fernández-Vázquez F, Pascual-Figal D, De la Torre Hernandez JM, Ferraro S, Vetrano A, Pérez-Rivera JA, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Agüero J, Pocock S, Ottani F, Fuster V, Ibáñez B; REBOOT-CNIC investigators. Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):291-301. doi: 10.1093/ehjcvp/pvab060.
  36. Management of acute coronary syndromes in older adults. Morici N, De Servi S, De Luca L, Crimi G, Montalto C, De Rosa R, De Luca G, Rubboli A, Valgimigli M, Savonitto S. Eur Heart J. 2022 Apr 19;43(16):1542-1553. doi: 10.1093/eurheartj/ehab391.
  37. Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes? De Luca L, Rubboli A, Bolognese L, Uguccioni M, Lucci D, Blengino S, Campodonico J, Meynet I, Brach Prever SM, Di Lenarda A, Gabrielli D, Gulizia MM; MATADOR-PCI Investigators. Open Heart. 2021 Jul;8(2):e001677. doi: 10.1136/openhrt-2021-001677.
  38. Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not? Rubboli A, Atar D. Am J Cardiovasc Drugs. 2022 Mar;22(2):113-115. doi: 10.1007/s40256-021-00488-4.
  39. Percutaneous artErial closure devices and ultrasound-guided Trans-femoRal puncture ObservatioNal InvestigatiOn: Insights from the PETRONIO registry. Iannopollo G, Nobile G, Lanzilotti V, Capecchi A, Verardi R, Bruno M, Somaschini A, Rubboli A, Di Pasquale G, Casella G. Catheter Cardiovasc Interv. 2022 Feb;99(3):795-803. doi: 10.1002/ccd.29828.
  40. Left atrial strain by speckle tracking predicts atrial fibrosis in patients undergoing heart transplantation. Lisi M, Mandoli GE, Cameli M, Pastore MC, Righini FM, Benfari G, Rubboli A, D'Ascenzi F, Focardi M, Tsioulpas C, Bernazzali S, Maccherini M, Lisi E, Lindqvist P, Valente S, Mondillo S, Henein MY. Eur Heart J Cardiovasc Imaging. 2022 Jun 1;23(6):829-835. doi: 10.1093/ehjci/jeab106.
  41. The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused. Rubboli A, Atar D. Eur J Intern Med. 2021 Aug;90:125-126. doi: 10.1016/j.ejim.2021.05.009. Epub 2021 Jun 3.
  42. The impact of periprocedural myocardial infarction on mortality in older adults with non-ST-segment elevation acute coronary syndrome: a pooled analysis of the FRASER and HULK studies. Erriquez A, Pavasini R, Biscaglia S, Tebaldi M, Tonet E, Maietti E, Cimaglia P, Grazzi G, Scoccia A, Cardelli LS, Verardi FM, Morelli C, Campana R, Rubboli A, Mazzoni G, Volpato S, Ferrari R, Campo G. J Cardiovasc Med (Hagerstown). 2021 Jul 1;22(7):546-552. doi: 10.2459/JCM.0000000000001146.
  43. Contrast Associated Acute Kidney Injury and Mortality in Older Adults with Acute Coronary Syndrome: A Pooled Analysis of the FRASER and HULK Studies. Pavasini R, Tebaldi M, Bugani G, Tonet E, Campana R, Cimaglia P, Maietti E, Grazzi G, Pompei G, Fabbri G, Fiorio A, Rubboli A, Mazzoni G, Vitali F, Serenelli M, Campo G, Biscaglia S. J Clin Med. 2021 May 16;10(10):2151. doi: 10.3390/jcm10102151.
  44. [Concepts and preconceptions on the use of direct oral anticoagulants in Italy: a Delphi consensus panel of the Atherosclerosis Thrombosis, Vascular Biology Study Group (ATBV)]. Rubboli A, Ageno W, Pengo V, Patti G. G Ital Cardiol (Rome). 2021 Jun;22(6):457-465. doi: 10.1714/3612.35930.
  45. How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. Rubboli A, Fresco C, Paciaroni M, Rocca B, Pecora D, Enea I, Cuccia C, Patti G. J Cardiovasc Med (Hagerstown). 2021 Dec 1;22(11):924-928. doi: 10.2459/JCM.0000000000001204.
  46. Transcatheter closure of ventricular septal defect: how and when?]. Moretti C, Aquilina M, Santoro G, Varani E, Vecchio S, Reggi A, Rubboli A. G Ital Cardiol (Rome). 2021 Mar;22(3 Suppl 1):43S-45S. doi: 10.1714/3578.35634.
  47. Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study. De Luca L, Di Lenarda A, Rubboli A, Bolognese L, Gonzini L, Fortuni F, Navazio A, Poletti F, Ledda A, Urbinati S, Gabrielli D, Gulizia MM; MATADOR-PCI Investigators. Eur J Intern Med. 2021 Jun;88:28-34. doi: 10.1016/j.ejim.2021.03.029.
  48. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP, Dudek D, Gilard M, Gorog DA, Grapsa J, Grove EL, Lancellotti P, Petronio AS, Rubboli A, Torracca L, Vilahur G, Witkowski A, Mehilli J. Eur Heart J. 2021 Jun 14;42(23):2265-2269. doi: 10.1093/eurheartj/ehab196.
  49. Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry. D'Ascenzo F, De Filippo O, Borin A, Barbieri L, Adamo M, Morici N, Truffa Giachet A, Iannaccone M, Crimi G, Gaido L, Bocchino PP, Pivato CA, Campo G, Trabattoni D, Chieffo A, Gaibazzi N, Angelini F, Rubboli A, Rognoni A, Musumeci G, Ugo F, Gili S, Cortese B, Vadalà P, Dusi V, Gallone G, Patti G, de Ferrari GM. Int J Cardiol. 2021 Jun 1;332:227-234. doi: 10.1016/j.ijcard.2021.03.063.
  50. Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Banerjee A, Chen S, Pasea L, Lai AG, Katsoulis M, Denaxas S, Nafilyan V, Williams B, Wong WK, Bakhai A, Khunti K, Pillay D, Noursadeghi M, Wu H, Pareek N, Bromage D, McDonagh TA, Byrne J, Teo JTH, Shah AM, Humberstone B, Tang LV, Shah ASV, Rubboli A, Guo Y, Hu Y, Sudlow CLM, Lip GYH, Hemingway H. Eur J Prev Cardiol. 2021 Dec 20;28(14):1599-1609. doi: 10.1093/eurjpc/zwaa155.
  51. [Clinical management of older, frail patients with atrial fibrillation. Operative strategies from a multidisciplinary expert group]. Marchionni N, Fumagalli S, Bo M, Boccanelli A, Boriani G, Rubboli A, Violi F, Di Pasquale G. G Ital Cardiol (Rome). 2021 Feb;22(2 Suppl 1):e3-e27. doi: 10.1714/3547.35222.
  52. [Periprocedural management of anticoagulation therapy and in-hospital outcomes in patients with warfarin indication undergoing percutaneous coronary intervention. Data from the WAR-STENT registry]. Fileti L, Sciahbasi A, Vecchio S, Saia F, Varani E, Calabrò P, Franco N, Palmieri C, Santi M, Imperadore F, Mameli S, Dallago M, Capecchi A, Galvani M, Piovaccari G, Rubboli A. G Ital Cardiol (Rome). 2021 Jan;22(1):62-67. doi: 10.1714/3502.34884.
  53. Clinical governance programme in patients with acute coronary syndrome: design and methodology of a quality improvement initiative. Leonardi S, Montalto C, Casella G, Grosseto D, Repetto A, Portolan M, Fortuni F, Ottani F, Galvani M, Cardelli LS, De Servi S, Rubboli A, De Ferrari GM, Oltrona Visconti L, Campo G. Open Heart. 2020 Dec;7(2):e001415. doi: 10.1136/openhrt-2020-001415.
  54. Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. De Luca L, Rubboli A, Bolognese L, Gonzini L, Urbinati S, Murrone A, Scotto di Uccio F, Ferrari F, Lucà F, Caldarola P, Lucci D, Gabrielli D, Di Lenarda A, Gulizia MM; MATADOR-PCI Investigators. BMJ Open. 2020 Dec 22;10(12):e041044. doi: 10.1136/bmjopen-2020-041044.
  55. Double vs. triple antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: does clinical presentation matter? Rubboli A, Collet JP. Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7(FI1):f61-f62. doi: 10.1093/ehjcvp/pvaa121.
  56. Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. Patti G, Lio V, Cavallari I, Gragnano F, Riva L, Calabrò P, Di Pasquale G, Pengo V, Rubboli A; Italian Study Group on Atherosclerosis, Thrombosis, Vascular Biology. Am J Cardiovasc Drugs. 2020 Dec;20(6):559-570. doi: 10.1007/s40256-020-00446-6.
  57. Antiplatelet therapy after coronary bypass grafting: which regimen and for whom? Rubboli A, Vecchio S. Eur Heart J Cardiovasc Pharmacother. 2021 Nov 3;7(6):527-528. doi: 10.1093/ehjcvp/pvaa091.
  58. Impact of the COVID-19 pandemic on coronary invasive procedures at two Italian high-volume referral centers. Fileti L, Vecchio S, Moretti C, Reggi A, Aquilina M, Balducelli M, Santarelli A, Grosseto D, Piovaccari G, Rubboli A. J Cardiovasc Med (Hagerstown). 2020 Nov;21(11):869-873. doi: 10.2459/JCM.0000000000001101.
  59. Electrocardiographic features of 431 consecutive, critically ill COVID-19 patients: an insight into the mechanisms of cardiac involvement. Bertini M, Ferrari R, Guardigli G, Malagù M, Vitali F, Zucchetti O, D'Aniello E, Volta CA, Cimaglia P, Piovaccari G, Corzani A, Galvani M, Ortolani P, Rubboli A, Tortorici G, Casella G, Sassone B, Navazio A, Rossi L, Aschieri D, Rapezzi C. Europace. 2020 Dec 23;22(12):1848-1854. doi: 10.1093/europace/euaa258.
  60. The ESC Working Group on Thrombosis. Vilahur G, Rocca B, Rubboli A, Sibbing D. Eur Heart J. 2020 Sep 1;41(33):3130-3131. doi: 10.1093/eurheartj/ehaa482.
  61. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. PMID: 32860505
  62. Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Vitolo M, Javed S, Capodanno D, Rubboli A, Boriani G, Lip GYH. Expert Rev Cardiovasc Ther. 2020 Sep;18(9):587-600. doi: 10.1080/14779072.2020.1808463.
  63. Impedance mapping with constant contact force on 3D electroanatomic map to characterize tissues at pulmonary veno-atrial junction.Tomasi C, Dal Monte A, Argnani MS, Corsi C, Giannotti F, Severi S, Rubboli A. J Interv Card Electrophysiol. 2021 Sep;61(3):469-477. doi: 10.1007/s10840-020-00845-4.
  64. Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: data from the nationwide MATADOR-PCI registry. De Luca L, Bolognese L, Rubboli A, Vetrano A, Callerame M, Rivetti L, Gonzini L, Gabrielli D, Di Lenarda A, Gulizia MM; MATADOR-PCI Investigators. Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e45-e47. doi: 10.1093/ehjcvp/pvaa088.
  65. Long-Term Risk of Major Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome: Prognostic Role of Complete Blood Cell Count. Morici N, Molinari V, Cantoni S, Rubboli A, Antolini L, Sacco A, Cattaneo M, Alicandro G, Oreglia JA, Oliva F, Giannattasio C, Brunelli D, La Vecchia C, Valgimigli M, Savonitto S. Angiology. 2020 Oct;71(9):831-839. doi: 10.1177/0003319720938619.
  66. [Arithmetic of non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation]. Rubboli A, Vecchio S. G Ital Cardiol (Rome). 2020 Jul;21(7):564. doi: 10.1714/3386.33647.
  67. [Impact of the COVID-19 pandemic on admissions for acute coronary syndrome: review of the literature and single-center experience]. Vecchio S, Fileti L, Reggi A, Moschini C, Lorenzetti S, Rubboli A. G Ital Cardiol (Rome). 2020 Jul;21(7):502-508. doi: 10.1714/3386.33635.
  68. [Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations - A position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology]. Patti G, Lio V, Cavallari I, Gragnano F, Riva L, Calabrò P, Di Pasquale G, Pengo V, Rubboli A. G Ital Cardiol (Rome). 2020 Jul;21(7):489-501. doi: 10.1714/3386.33634.
  69. Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. Rubboli A, Valgimigli M, Capodanno D, Lip GYH. Eur Heart J Cardiovasc Pharmacother. 2021 Jan 16;7(1):68-73. doi: 10.1093/ehjcvp/pvaa047.
  70. Why the four non-vitamin K-antagonist oral anticoagulants are actually five. Rubboli A. Eur J Intern Med. 2020 Aug;78:152-153. doi: 10.1016/j.ejim.2020.04.010.
  71. Exercise intervention improves quality of life in older adults after myocardial infarction: randomised clinical trial. Campo G, Tonet E, Chiaranda G, Sella G, Maietti E, Bugani G, Vitali F, Serenelli M, Mazzoni G, Ruggiero R, Villani G, Biscaglia S, Pavasini R, Rubboli A, Campana R, Caglioni S, Volpato S, Myers J, Grazzi G. Heart. 2020 Nov;106(21):1658-1664. doi: 10.1136/heartjnl-2019-316349.
  72. Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, Siller-Matula JM, Storey RF, Vranckx P, Rocca B. Eur Heart J Cardiovasc Pharmacother. 2021 Mar 15;7(2):125-140. doi: 10.1093/ehjcvp/pvaa009.
  73. Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations. Rubboli A, Lip GYH. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):197-198. doi: 10.1093/ehjcvp/pvaa003.
  74. From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Rubboli A, Barbaresi E, Rocca B. Cardiovasc Drugs Ther. 2020 Feb;34(1):143-144. doi: 10.1007/s10557-019-06903-y.
  75. Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease. Rocca B, Rubboli A, Zaccardi F. Eur J Prev Cardiol. 2019 Dec;26(2_suppl):92-105. doi: 10.1177/2047487319880045.
  76. [The ENTRUST-AF PCI trial]. Rubboli A. G Ital Cardiol (Rome). 2019 Oct;20(10):541-542. doi: 10.1714/3228.32052.
  77. Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Pavasini R, Maietti E, Tonet E, Bugani G, Tebaldi M, Biscaglia S, Cimaglia P, Serenelli M, Ruggiero R, Vitali F, Galvani M, Minarelli M, Rubboli A, Bernucci D, Volpato S, Campo G. Cardiovasc Drugs Ther. 2019 Oct;33(5):523-532. doi: 10.1007/s10557-019-06911-y.
  78. Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy-Current Evidence and Practice. Geisler T, Jorbenadze R, Popov AF, Mueller KL, Rath D, Droppa M, Schreieck J, Seizer P, Storey RF, Kristensen SD, Rubboli A, Gorog D, Aradi D, Sibbing D, Huber K, Gawaz M, Ten Berg J. Thromb Haemost. 2019 Oct;119(10):1590-1605. doi: 10.1055/s-0039-1694751.
  79. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Kalarus Z, Svendsen JH, Capodanno D, Dan GA, De Maria E, Gorenek B, Jędrzejczyk-Patej E, Mazurek M, Podolecki T, Sticherling C, Tfelt-Hansen J, Traykov V, Lip GYH, Fauchier L, Boriani G, Mansourati J, Blomström-Lundqvist C, Mairesse GH, Rubboli A, Deneke T, Dagres N, Steen T, Ahrens I, Kunadian V, Berti S. Europace. 2019 Oct 1;21(10):1603-1604. doi: 10.1093/europace/euz163.
  80. [Optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting: the real question nowadays is...]. Rubboli A, Ricci Lucchi G, Vecchio S. G Ital Cardiol (Rome). 2019 Jun;20(6):396. doi: 10.1714/3165.31474.
  81. And now we have the AUGUSTUS … How will it impact on antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention? [https://pubmed.ncbi.nlm.nih.gov/31130303/] Rubboli A. Eur J Intern Med. 2019 Jul;65:1-3. doi: 10.1016/j.ejim.2019.05.019.
  82. After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention? Rubboli A, Lisi M. Cardiovasc Drugs Ther. 2019 Aug;33(4):499-500. doi: 10.1007/s10557-019-06886-w.
  83. Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice. Rubboli A. Eur J Intern Med. 2019 Apr;62:e11-e12. doi: 10.1016/j.ejim.2019.01.005. Epub 2019 Jan 20.
  84. Fourth universal definition of myocardial infarction (2018). Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Eur Heart J. 2019 Jan 14;40(3):237-269. doi: 10.1093/eurheartj/ehy462.
  85. Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. Riva L, Ageno W, Di Pasquale G, Agnelli G, Rubboli A. Int J Cardiol. 2018 Oct 15;269:75-79. doi: 10.1016/j.ijcard.2018.07.133.
  86. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K; ESC Scientific Document Group. Europace. 2019 Feb 1;21(2):192-193. doi: 10.1093/europace/euy174.
  87. Oral anticoagulation alone for concomitant stable coronary artery disease and atrial fibrillation: A definitive strategy? Rubboli A. Int J Cardiol. 2018 Aug 1;264:95-96. doi: 10.1016/j.ijcard.2018.04.023.
  88. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, Patrono C, Rubboli A, Seljeflot I, Sibbing D, Siegbahn A, Ten Berg J, Vilahur G, Verheugt FWA, Wallentin L, Weiss TW, Wojta J, Storey RF. Eur Heart J. 2018 May 14;39(19):1672-1686f. doi: 10.1093/eurheartj/ehy066.
  89. What is the Role for Glycoprotein IIb/IIIa Inhibitor Use in the Catheterization Laboratory in the Current Era? Rubboli A, Patti G. Curr Vasc Pharmacol. 2018;16(5):451-458. doi: 10.2174/1570161116666180117102422.
  90. Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry. Nammas W, Kiviniemi T, Schlitt A, Rubboli A, Valencia J, Lip GYH, Karjalainen PP, Biancari F, Juhani Airaksinen KE. Int J Cardiol. 2018 Feb 15;253:35-39. doi: 10.1016/j.ijcard.2017.07.074.
  91. What is the significance, if any, of the increased incidence of stent thrombosis with dual therapy of dabigatran 110mg twice daily and clopidogrel in the RE-DUAL PCI trial? Rubboli A. Eur J Intern Med. 2018 Apr;50:e27-e28. doi: 10.1016/j.ejim.2017.12.009.
  92. Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. Lahtela HM, Bah A, Kiviniemi T, Nammas W, Schlitt A, Rubboli A, Karjalainen PP, Proietti M, Hartikainen JEK, Lip GYH, Airaksinen KEJ. Clin Cardiol. 2017 Dec;40(12):1264-1270. doi: 10.1002/clc.22821. E
  93. [Low or reduced? Semantics of the doses of new oral anticoagulants]. Rubboli A. G Ital Cardiol (Rome). 2017 Sep;18(9 Suppl 2):3S-9S. doi: 10.1714/2795.28297. P
  94. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Lip GYH, Collet JP, Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F, Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N, Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B; ESC Scientific Document Group. Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240. P
  95. Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? Rubboli A. Eur J Intern Med. 2017 Dec;46:e40-e41. doi: 10.1016/j.ejim.2017.10.001.
  96. Should CT pulmonary angiography be routinely performed after ultrasound-facilitated, catheter-directed thrombolysis in intermediate-high risk pulmonary embolism? Rubboli A, Lanzilotti V, Pavesi PC, Casella G, DI Pasquale G. Minerva Cardioangiol. 2017 Dec;65(6):661-663. doi: 10.23736/S0026-4725.17.04397-3.
  97. Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation. De Luca L, Casella G, Rubboli A, Gonzini L, Lucci D, Boccanelli A, Chiarella F, Di Chiara A, De Servi S, Di Lenarda A, Di Pasquale G, Savonitto S. Int J Cardiol. 2017 Dec 1;248:369-375. doi: 10.1016/j.ijcard.2017.08.019.
  98. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Ageno W, Beyer-Westendorf J, Rubboli A. Expert Opin Pharmacother. 2017 Sep;18(13):1325-1332. doi: 10.1080/14656566.2017.1361405. Epub 2017 Aug 11.
  99. Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GY; AFCAS Study Group. Am Heart J. 2017 Aug;190:86-93. doi: 10.1016/j.ahj.2017.05.016. Epub 2017 Jun 3.
  100. [OAC and NOAC... and why not also VOAC? Considerations on the terminology and acronyms of oral anticoagulants]. [https://pubmed.ncbi.nlm.nih.gov/28398384/] Rubboli A, Cuccia C, Fresco C. G Ital Cardiol (Rome). 2017 Mar;18(3):251. doi: 10.1714/2674.27403.
  101. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Suggested strategies tailored to an integrated evaluation of different risk profiles. Patti G, Rubboli A. Eur J Intern Med. 2017 Jun;41:e10-e11. doi: 10.1016/j.ejim.2017.03.017.
  102. Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry. Rubboli A, Saia F, Sciahbasi A, Leone AM, Palmieri C, Bacchi-Reggiani ML, Calabrò P, Bordoni B, Piccalò G, Franco N, Nicolino A, Magnavacchi P, Vignali L, Mameli S, Dallago M, Maggiolini S, Steffanon L, Piovaccari G, Di Pasquale G; WARfarin and Coronary STENTing (WAR-STENT) Study group. Cardiovasc Revasc Med. 2017 Sep;18(6):425-430. doi: 10.1016/j.carrev.2017.03.015.
  103. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G. Adv Ther. 2017 Mar;34(3):620-637. doi: 10.1007/s12325-017-0488-9.
  104. New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. Rubboli A, Agewall S, Huber K, Lip GYH. Eur J Intern Med. 2017 May;40:e11-e12. doi: 10.1016/j.ejim.2017.01.003. Epub 2017 Jan 10.
  105. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GYH; AFCAS Study Group. Clin Res Cardiol. 2017 Jun;106(6):420-427. doi: 10.1007/s00392-016-1071-0.
  106. Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship. Rubboli A, Verheugt FWA. Int J Cardiol. 2016 Nov 15;223:519-520. doi: 10.1016/j.ijcard.2016.08.207.
  107. Changes in antithrombotic therapy after a cerebrovascular or coronary ischemic event in the WARfarin and coronary STENTing (WAR-STENT) registry. Rubboli A, Palmieri C, Piovaccari G, DI Pasquale G, Briguori C, Margheri M; Group for the WARfarin and coronary STENTing (WAR-STENT) Study. Panminerva Med. 2016 Sep;58(3):242-3.
  108. [The ENGAGE AF-TIMI 48 study]. Rubboli A, Colonna P. G Ital Cardiol (Rome). 2015 Sep;16(9):457-61. doi: 10.1714/1988.21512.
  109. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. Bavishi C, Koulova A, Bangalore S, Sawant A, Chatterjee S, Ather S, Valencia J, Sarafoff N, Rubboli A, Airaksinen JK, Lip GY, Tamis-Holland JE. Catheter Cardiovasc Interv. 2016 Jul;88(1):E12-22. doi: 10.1002/ccd.26234.
  110. Anti-platelet pre-treatment for atrial fibrillation patients on warfarin referred for coronary angiography/stenting because of non-ST-elevation acute coronary syndrome: An alternative proposal. Rubboli A, Di Pasquale G. Int J Cardiol. 2015 Dec 15;201:494-6. doi: 10.1016/j.ijcard.2015.08.122.
  111. Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter? Rubboli A. Curr Med Res Opin. 2015;31(10):1845-7. doi: 10.1185/03007995.2015.1086993.
  112. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. Rubboli A, Agewall S, Huber K, Lip GY. Int J Cardiol. 2015 Oct 1;196:133-8. doi: 10.1016/j.ijcard.2015.06.006.
  113. Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. Lahtela HM, Kiviniemi TO, Puurunen MK, Schlitt A, Rubboli A, Ylitalo A, Valencia J, Lip GY, Airaksinen KE. PLoS One. 2015 Jun 1;10(6):e0128492. doi: 10.1371/journal.pone.0128492.
  114. Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry. Rubboli A, Calabrò P, Saia F, Sciahbasi A; WARfarin and coronary STENTing (WAR-STENT) Study Group. J Cardiovasc Med (Hagerstown). 2015 Jul;16(7):520-1. doi: 10.2459/JCM.0000000000000287.
  115. Effective Treatment of Intermediate-Risk Pulmonary Embolism by Manual Thrombus Aspiration. A Report of Two Cases. Sebik R, Cortese B, Buccheri D, Silva-Orrego P, Rubboli A. Heart Lung Circ. 2015 Aug;24(8):e130-2. doi: 10.1016/j.hlc.2015.03.024.
  116. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. D'Ascenzo F, Taha S, Moretti C, Omedè P, Grossomarra W, Persson J, Lamberts M, Dewilde W, Rubboli A, Fernández S, Cerrato E, Meynet I, Ballocca F, Barbero U, Quadri G, Giordana F, Conrotto F, Capodanno D, DiNicolantonio J, Bangalore S, Reed M, Meier P, Zoccai G, Gaita F. Am J Cardiol. 2015 May 1;115(9):1185-93. doi: 10.1016/j.amjcard.2015.02.003. Epub 2015 Feb 12.
  117. Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study. Kiviniemi T, Airaksinen KE, Rubboli A, Biancari F, Valencia J, Lip GY, Karjalainen PP, Weber M, Laine M, Kirchhof P, Schlitt A; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group. Int J Cardiol. 2015 Mar 15;183:105-10. doi: 10.1016/j.ijcard.2015.01.056.
  118. [Diagnosis and therapy of pulmonary arterial hypertension in Italy: results of the INCIPIT2 survey]. Enea I, Roncon L, Azzarito M, Bongarzoni A, Casazza F, D'Agostino C, Favretto G, Rubboli A, Zonzin P. G Ital Cardiol (Rome). 2014 Dec;15(12):710-6. doi: 10.1714/1718.18776.
  119. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. Rubboli A, Saia F, Sciahbasi A, Bacchi-Reggiani ML, Steffanon L, Briguori C, Calabrò P, Palmieri C, Rizzi A, Imperadore F, Sangiorgi GM, Valgimigli M, Carosio G, Steffenino G, Galvani M, Di Pasquale G, La Vecchia L, Maggioni AP, Bolognese L; WARfarin and Coronary STENTing (WAR-STENT) Study Group. J Invasive Cardiol. 2014 Nov;26(11):563-9.
  120. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview. Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marín F, Bhatt DL, Lip GY. Thromb Haemost. 2014 Dec;112(6):1080-7. doi: 10.1160/TH14-08-0681.
  121. Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention. Kiviniemi T, Puurunen M, Schlitt A, Rubboli A, Karjalainen P, Nammas W, Kirchhof P, Biancari F, Lip GY, Airaksinen KJ. Circ J. 2014;78(11):2674-81. doi: 10.1253/circj.cj-14-0792.
  122. New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry (REgistro Regionale AngiopLastiche Dell'Emilia-Romagna). Vignali L, Saia F, Belotti LM, Solinas E, Guastaroba P, Rubboli A, Manari A, Mehran R, Ardissino D, De Palma R. Catheter Cardiovasc Interv. 2015 Apr;85(5):797-806. doi: 10.1002/ccd.25675.
  123. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D; Document Reviewers; Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Eur Heart J. 2014 Dec 1;35(45):3155-79. doi: 10.1093/eurheartj/ehu298.
  124. Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. Puurunen M, Kiviniemi T, Nammas W, Schlitt A, Rubboli A, Nyman K, Karjalainen P, Kirchhof P, Lip GY, Airaksinen JK. BMJ Open. 2014 May 13;4(5):e004700. doi: 10.1136/bmjopen-2013-004700.
  125. Performance of bleeding risk-prediction scores in patients with atrial fibrillation undergoing percutaneous coronary intervention. Kiviniemi T, Puurunen M, Schlitt A, Rubboli A, Karjalainen P, Vikman S, Niemelä M, Lahtela H, Lip GY, Airaksinen KE. Am J Cardiol. 2014 Jun 15;113(12):1995-2001. doi: 10.1016/j.amjcard.2014.03.038.
  126. Percutaneous rheolytic thrombectomy with the AngioJet System for the treatment of intermediate-risk acute pulmonary embolism: a case report and an appraisal of contemporary indications and technique. Vecchio S, Varani E, Nuzzo A, Balducelli M, Vecchi G, Aquilina M, Rubboli A, Margheri M. Minerva Cardioangiol. 2014 Apr;62(2):221-8.
  127. Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin therapy. Kiviniemi T, Karjalainen P, Niemelä M, Rubboli A, Lip GY, Schlitt A, Nammas W, Airaksinen KE. Thromb Res. 2014 Apr;133(4):695-6. doi: 10.1016/j.thromres.2014.01.038.
  128. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, Valencia J, Laine M, Kirchhof P, Niemelä M, Vikman S, Lip GY, Airaksinen KE; AFCAS Study Group. Clin Cardiol. 2014 Jun;37(6):357-64. doi: 10.1002/clc.22254.
  129. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Puurunen MK, Kiviniemi T, Schlitt A, Rubboli A, Dietrich B, Karjalainen P, Nyman K, Niemelä M, Lip GY, Airaksinen KE. Thromb Res. 2014 Apr;133(4):560-6. doi: 10.1016/j.thromres.2014.01.007.
  130. [ANMCO/SICI-GISE document on antiplatelet therapy in patients with acute coronary syndrome]. De Luca L, Bolognese L, Valgimigli M, Ceravolo R, Danzi GB, Piccaluga E, Rakar S, Cremonesi A, Bovenzi FM; Gruppo di Lavoro dell'Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Societa Italiana di Cardiologia Invasiva (SICI-GISE). G Ital Cardiol (Rome). 2013 Dec;14(12):839-66. doi: 10.1714/1371.15242.
  131. Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Rubboli A, Oldgren J, Marìn F, Lip G. Intern Emerg Med. 2013 Dec;8(8):673-80. doi: 10.1007/s11739-013-1008-9.
  132. [The WOEST study]. [https://pubmed.ncbi.nlm.nih.gov/23903275/] Rubboli A, Limbruno U. G Ital Cardiol (Rome). 2013 Sep;14(9):564-8. doi: 10.1714/1311.14481.
  133. Antiplatelet therapy and anticoagulants. Schlitt A, Rubboli A, Airaksinen KE, Lip GY. Lancet. 2013 Jul 6;382(9886):24-5. doi: 10.1016/S0140-6736(13)61521-4.
  134. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study. Schlitt A, Rubboli A, Lip GY, Lahtela H, Valencia J, Karjalainen PP, Weber M, Laine M, Kirchhof P, Niemelä M, Vikman S, Buerke M, Airaksinen KE; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group). Catheter Cardiovasc Interv. 2013 Dec 1;82(7):E864-70. doi: 10.1002/ccd.25064.
  135. Thrombocytopenia in patients with atrial fibrillation on oral anticoagulation undergoing percutaneous coronary intervention. Kiviniemi T, Karjalainen P, Rubboli A, Schlitt A, Tuomainen P, Niemelä M, Laine M, Biancari F, Lip GY, Airaksinen KE. Am J Cardiol. 2013 Aug 15;112(4):493-8. doi: 10.1016/j.amjcard.2013.04.007.
  136. Letter by Marín et al regarding article, "Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study". Marín F, Fauchier L, Rubboli A. Circulation. 2013 Apr 30;127(17):e584. doi: 10.1161/CIRCULATIONAHA.112.141838.
  137. In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. Rubboli A, Sciahbasi A, Briguori C, Saia F, Palmieri C, Moroni LA, Calabrò P, Leone AM, Franco N, Valgimigli M, Varani E, Santi M, Pasqualini P, Capecchi A, Piccalò G, Margheri M, di Pasquale G, Galvani M, Bolognese L, Gonzini L, Maggioni AP; WARfarin and coronary STENTing registry. J Invasive Cardiol. 2013 Apr;25(4):170-6.
  138. Clinical management of rivaroxaban-treated patients. Palareti G, Ageno W, Ferrari A, Filippi A, Imberti D, Pengo V, Rubboli A, Toni D. Expert Opin Pharmacother. 2013 Apr;14(5):655-67. doi: 10.1517/14656566.2013.773310.
  139. Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis. Menozzi M, Rubboli A, Manari A, De Palma R, Grilli R. Thromb J. 2012 Oct 18;10(1):22. doi: 10.1186/1477-9560-10-22.
  140. The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: Facts and questions. [https://pubmed.ncbi.nlm.nih.gov/22783307/] Rubboli A. J Geriatr Cardiol. 2011 Dec;8(4):207-14. doi: 10.3724/SP.J.1263.2011.00207.
  141. Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemelä M, Vikman S, Puurunen M, Weber M, Valencia J, Biancari F, Lip GY, Airaksinen KE; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group. Circ J. 2012;76(6):1363-8. doi: 10.1253/circj.cj-11-1206.
  142. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). Rubboli A, Magnavacchi P, Guastaroba P, Saia F, Vignali L, Giacometti P, Franco N, Benassi A, Varani E, Campo G, Manari A, De Palma R, Marzocchi A. Am J Cardiol. 2012 May 15;109(10):1411-7. doi: 10.1016/j.amjcard.2012.01.353.
  143. Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. Valgimigli M, Saia F, Guastaroba P, Menozzi A, Magnavacchi P, Santarelli A, Passerini F, Sangiorgio P, Manari A, Tarantino F, Margheri M, Benassi A, Sangiorgi MG, Tondi S, Marzocchi A; REAL Registry Investigators. JACC Cardiovasc Interv. 2012 Jan;5(1):23-35. doi: 10.1016/j.jcin.2011.08.018.
  144. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. Rubboli A, Becattini C, Verheugt FW. World J Cardiol. 2011 Nov 26;3(11):351-8. doi: 10.4330/wjc.v3.i11.351.
  145. Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms. Squizzato A, Luciani D, Rubboli A, Di Gennaro L, Landolfi R, De Luca C, Porro F, Moia M, Testa S, Imberti D, Bertolini G. Intern Emerg Med. 2013 Dec;8(8):695-702. doi: 10.1007/s11739-011-0725-1.
  146. Coronary stenting for ST-elevation myocardial infarction vs. other indications in patients on oral anticoagulation: any difference in in-hospital management and outcome? Vecchio S, Zanolla L, Valencia J, Colletta M, Capecchi A, Franco N, Piovaccari G, Margheri M, Di Pasquale G, Rubboli A; WARfarin and Coronary STENTing (WAR-STENT) Study Group. Minerva Cardioangiol. 2011 Oct;59(5):499-506.
  147. The management of patients on oral anticoagulation undergoing coronary stent implantation: a survey among interventional cardiologists from eight European countries. Rubboli A, Dewilde W, Huber K, Eeckhout E, Herzfeld I, Valencia J, Windecker S, Airaksinen KE, Lip GY. J Interv Cardiol. 2012 Apr;25(2):163-9. doi: 10.1111/j.1540-8183.2011.00683.x.
  148. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Huber K, Airaksinen KJ, Cuisset T, Marín F, Rubboli A, Lip GY. Thromb Haemost. 2011 Oct;106(4):569-71. doi: 10.1160/TH11-08-0602. Epub 2011 Sep 12.
  149. Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options. Rubboli A, Kovacic JC, Mehran R, Lip GYH. Chest. 2011 May;139(5):981-987. doi: 10.1378/chest.10-2719.
  150. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P; Document reviewers:; Collet JP, Rubboli A, Poli D, Camm J. Europace. 2011 May;13(5):723-46. doi: 10.1093/europace/eur126.
  151. The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update. Rubboli A. Intern Emerg Med. 2012 Aug;7(4):299-304. doi: 10.1007/s11739-011-0555-1.
  152. Antithrombotic management of patients on oral anticoagulation undergoing coronary artery stenting. Rubboli A. World J Cardiol. 2010 Mar 26;2(3):64-7. doi: 10.4330/wjc.v2.i3.64.
  153. How to manage antithrombotic treatment during percutaneous coronary interventions in patients receiving long-term oral anticoagulation: to "bridge" or not to "bridge"? Airaksinen KE, Schlitt A, Rubboli A, Karjalainen P, Lip GY. EuroIntervention. 2010 Sep;6(4):520-6. doi: 10.4244/EIJ30V6I4A86.
  154. [Echocardiographic alterations suggestive of pulmonary hypertension in the Italian ultrasonography laboratories. Epidemiological data from the INCIPIT study (INCidence of Pulmonary Hypertension in Italian ulTrasonography laboratories)]. Enea I, Ghio S, Bongarzoni A, Casazza F, D'Armini AM, Favretto G, Roncon L, Rubboli A, Serafini O, Zonzin P, D'Agostino C. G Ital Cardiol (Rome). 2010 May;11(5):402-7.
  155. Bleeding after coronary stenting in patients on oral anticoagulation: who is guilty? Rubboli A, Schlitt A, Airaksinen J, Lip GY. EuroIntervention. 2010 Jan;5(6):649-50; author reply 651. doi: 10.4244/5i6a105.
  156. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. Rubboli A, Colletta M, Valencia J, Capecchi A, Franco N, Zanolla L, La Vecchia L, Piovaccari G, Di Pasquale G; WARfarin and Coronary STENTing (WAR-STENT) Study Group. J Interv Cardiol. 2009 Aug;22(4):390-7. doi: 10.1111/j.1540-8183.2009.00468.x.
  157. A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. Rubboli A, Bolognese L, Di Pasquale G, Galvani M, La Vecchia L, Maggioni AP. J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):200-3. doi: 10.2459/JCM.0b013e3283212f07.
  158. Mechanisms of late stent malapposition after primary stenting in ST-elevation myocardial infarction: a subanalysis of the selection trial. Chechi T, Vecchio S, Lilli A, Giuliani G, Spaziani G, Baldereschi G, Montereggi A, Rubboli A, Margheri M. J Interv Cardiol. 2009 Jun;22(3):201-6. doi: 10.1111/j.1540-8183.2009.00461.x.
  159. Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism. Chechi T, Vecchio S, Spaziani G, Giuliani G, Giannotti F, Arcangeli C, Rubboli A, Margheri M. Catheter Cardiovasc Interv. 2009 Mar 1;73(4):506-13. doi: 10.1002/ccd.21858.
  160. [How and when to use dual antiplatelet treatment in the patient treated with oral anticoagulants?]. [https://pubmed.ncbi.nlm.nih.gov/19058665/] Rubboli A, Di Pasquale G. G Ital Cardiol (Rome). 2008 Nov;9(11):745-52.
  161. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Rubboli A, Halperin JL. Thromb Haemost. 2008 Nov;100(5):752-3.
  162. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY. Ann Med. 2008;40(6):428-36. doi: 10.1080/07853890802089786.
  163. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, Varani E, Piovaccari G, Menozzi A, Percoco G, Benassi A, Rusticali G, Marzaroli P, Guastaroba P, Grilli R, Maresta A, Marzocchi A. Am J Cardiol. 2008 Apr 1;101(7):947-52. doi: 10.1016/j.amjcard.2007.11.055.
  164. Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction. Rubboli A. Curr Cardiol Rev. 2008 Feb;4(1):63-71. doi: 10.2174/157340308783565438.
  165. Utilizing enoxaparin in the management of STEMI. Rubboli A, Capecchi A, Di Pasquale G. Vasc Health Risk Manag. 2007;3(5):691-700.
  166. Triple therapy of warfarin, aspirin and a thienopyridine for patients treated with vitamin K antagonists undergoing coronary stenting. A review of the evidence. Rubboli A, Di Pasquale G. Intern Emerg Med. 2007 Oct;2(3):177-81. doi: 10.1007/s11739-007-0055-5.
  167. Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting: a review of the available evidence and practical suggestions for the clinician. Rubboli A, Verheugt FW. Int J Cardiol. 2008 Jan 24;123(3):234-9. doi: 10.1016/j.ijcard.2007.02.017.
  168. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Coron Artery Dis. 2007 May;18(3):193-9. doi: 10.1097/MCA.0b013e328012a964.
  169. The combination of anticoagulant and anti-platelet therapy in patients with atrial fibrillation: a comment on the recent ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Rubboli A, Di Pasquale G. Eur Heart J. 2006 Dec;27(23):2908-9; author reply 2909-10. doi: 10.1093/eurheartj/ehl348.
  170. Contemporary antithrombotic treatment after coronary stenting in patients with indication for long-term anticoagulation. Rubboli A, Brancaleoni R, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Minerva Cardioangiol. 2006 Oct;54(5):687-93.
  171. Left ventricular pseudoaneurysm protruding outside the chest wall. Colletta M, Rubboli A, Di Pasquale G. J Cardiovasc Med (Hagerstown). 2006 Oct;7(10):779. doi: 10.2459/01.JCM.0000247328.88030.f6.
  172. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature. Rubboli A, Ottani F, Capecchi A, Brancaleoni R, Galvani M, Swahn E. Cardiology. 2007;107(2):132-9. doi: 10.1159/000094659.
  173. [Antithrombotic treatment after coronary stenting in patients with an indication to oral anticoagulation: what are the possible strategies?]. Rubboli A, Di Pasquale G. G Ital Cardiol (Rome). 2006 Jan;7(1):68-73.
  174. Optimal antithrombotic treatment in patients with an indication for long-term anticoagulation undergoing coronary artery stenting. Rubboli A, Di Pasquale G. Future Cardiol. 2006 Mar;2(2):205-13. doi: 10.2217/14796678.2.2.205.
  175. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose. Rubboli A, Gatti C, Spinolo L, Parollo R, Spitali G, Maresta A. Minerva Cardioangiol. 2006 Feb;54(1):131-7.
  176. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Rubboli A, Milandri M, Castelvetri C, Cosmi B. Cardiology. 2005;104(2):101-6. doi: 10.1159/000086918.
  177. Oral anticoagulation and mechanical heart valves: the case of the elderly and pregnancy. Rubboli A, Di Pasquale G. Ital Heart J. 2005 May;6(5):405-8.
  178. Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation. Rubboli A, Colletta M, Di Pasquale G. Am Heart J. 2005 Feb;149(2):E1. doi: 10.1016/j.ahj.2004.08.019. P
  179. Antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary artery stenting: safety and efficacy data from a single center. Rubboli A, Colletta M, Sangiorgio P, Di Pasquale G. Ital Heart J. 2004 Dec;5(12):919-25.
  180. Antithrombotic treatment after coronary artery stenting in patients on chronic oral anticoagulation: an international survey of current clinical practice. Rubboli A, Colletta M, Sangiorgio P, Di Pasquale G. Ital Heart J. 2004 Nov;5(11):851-6.
  181. Frequency and determinants of direct stenting in routine percutaneous coronary interventions: data on 835 consecutive procedures in a single center. La Vecchia L, Vincenzi P, Favero L, Martini M, Rubboli A, Ottani F, Varotto L, Fontanelli A. Ital Heart J. 2004 Oct;5(10):749-54.
  182. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. La Vecchia L, Ottani F, Favero L, Spadaro GL, Rubboli A, Boanno C, Mezzena G, Fontanelli A, Jaffe AS. Heart. 2004 Jun;90(6):633-7. doi: 10.1136/hrt.2003.019745.
  183. More about transport for primary PCI in AMI. Rubboli A. Eur Heart J. 2004 Apr;25(8):708. doi: 10.1016/j.ehj.2004.03.001.
  184. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis. Casella G, Ottani F, Pavesi PC, Sangiorgio P, Rubboli A, Galvani M, Fontanelli A, Bracchetti D. Ital Heart J. 2003 Oct;4(10):677-84.
  185. Enoxaparin for the treatment of acute myocardial infarction with persistent ST-segment elevation. Rubboli A, Herzfeld I, Maresta A. Minerva Cardioangiol. 2003 Oct;51(5):463-70, 470-4. P
  186. Systematic coronary stenting after failed thrombolysis in high-risk patients with acute myocardial infarction: procedural results and long-term follow-up. La Vecchia L, Favero L, Martini M, Vincenzi P, Rubboli A, Ottani F, Bottero M, Fontanelli A. Coron Artery Dis. 2003 Aug;14(5):395-400. doi: 10.1097/01.mca.0000085136.16622.33.
  187. Association of cholesterol levels and occurrence of angiographically detectable endothelial disruption during coronary angioplasty. Rubboli A, Euler DE, Sangiorgio P, Casella G, La Vechia L, Fontanelli A, Bracchetti D. Clin Cardiol. 2003 Jul;26(7):336-40. doi: 10.1002/clc.4950260708. P
  188. Massive coronary artery calcification in a young adult with end-stage renal disease undergoing hemodialysis. Rubboli A, La Vecchia L, Fontanelli A. Ital Heart J. 2003 Feb;4(2):142-3.
  189. Antonio Maria Valsalva. Fransson SG, Rubboli A. Clin Cardiol. 2003 Feb;26(2):102-3. doi: 10.1002/clc.4960260211.
  190. [Relation between cardiology and cardiosurgery in a center without cardiosurgery: an organizational proposal in the coronary syndromes]. Casella G, Pavesi PC, Sangiorgio P, Rubboli A, Nobile G, Gordini G, Pierangeli A, Bracchetti D. Ital Heart J Suppl. 2002 Mar;3(3):319-30.
  191. Inverse relationship between volume and outcome in coronary angioplasty: what are the implications for clinical practice? Rubboli A. Circulation. 2002 May 14;105(19):e173. doi: 10.1161/01.cir.0000016124.25320.4e.
  192. Outcome of percutaneous coronary angioplasty (PTCA) performed in a low-volume institution by low-volume operators, evaluated by means of the one-month major adverse cardiac event rate. Rubboli A, Brancaleoni R, Euler DE, Casella G, La Vecchia L, Fontanelli A, Sangiorgio P, Bracchetti D. Minerva Cardioangiol. 2001 Dec;49(6):357-62.
  193. Images in cardiovascular medicine. Severe "candy-wrapper" spasm of the right coronary artery associated with direct stent implantation. Rubboli A, La Vecchia L, Fontanelli A. Ital Heart J. 2001 Oct;2(10):789.
  194. Ticlopidine versus oral anticoagulation for coronary stenting. Cosmi B, Rubboli A, Castelvetri C, Milandri M. Cochrane Database Syst Rev. 2001;2001(4):CD002133. doi: 10.1002/14651858.CD002133.
  195. Appropriateness of the use of coronary angiography in a population of patients with ischemic heart disease. Rubboli A, La Vecchia L, Casella G, Sangiorgio P, Bracchetti D. Ital Heart J. 2001 Sep;2(9):696-701.
  196. Acute total occlusion of the right coronary artery by a pellet. La Vecchia L, Rubboli A, Paccanaro M, Varotto L, Fontanelli A. Circulation. 2001 Aug 21;104(8):E40. doi: 10.1161/hc3301.094153.
  197. [Bologna--a city with close ties to medical history]. Fransson SG, Rubboli A. Lakartidningen. 2001 May 9;98(19):2357-8.
  198. Guidelines on the diagnosis of acute pulmonary embolism and their applicability in clinical practice. Rubboli A, Euler DE. Eur Heart J. 2001 May;22(9):798-9. doi: 10.1053/euhj.2000.2488.
  199. Current perspectives The diagnosis of acute pulmonary embolism. A review of the literature and current clinical practice. Rubboli A, Euler DE. Ital Heart J. 2000 Sep;1(9):585-94.
  200. [Apropos the diagnosis of acute pulmonary embolism]. Rubboli A. Cardiologia. 1999 Sep;44(9):843-4.
  201. [Initial experience with the use of abciximab in the salvage treatment of acute coronary thrombosis in the Hemodynamics Laboratory]. Rubboli A, Fransson SG, Wiklund G, Sangiorgio P, Bracchetti D, Stenport G. Cardiologia. 1998 Nov;43(11):1221-9.
  202. [Verapamil in myocardial infarct]. [https://pubmed.ncbi.nlm.nih.gov/9534314/] Rubboli A, Sangiorgio P, Bracchetti D. Cardiologia. 1997 Dec;42(12):1215-20.
  203. Diagnostic approach to acute pulmonary embolism in a general hospital. A two-year analysis. Rubboli A, Leonardi G, de Castro U, Bracchetti D. G Ital Cardiol. 1998 Feb;28(2):123-30. P
  204. Images in cardiovascular medicine. Demonstration of massive pulmonary embolism with spiral volumetric CT. Rubboli A, Burzi M, Rossi MS, Sangiorgio P, Sartoni Galloni S, Bracchetti D. Circulation. 1997 Oct 7;96(7):2464. doi: 10.1161/01.cir.96.7.2464.
  205. [Use of verapamil vs. beta blockers in patients with myocardial infarct. Retrospective evaluation of the yearly case load of a coronary care unit]. Rubboli A, Colletta M, Sangiorgio P, Casella G, Pavesi PC, Bracchetti D. Minerva Cardioangiol. 1997 Jul-Aug;45(7-8):349-56.
  206. [ST segment depression during recovery after treadmill exercise test in stable patients with previous myocardial infarction]. Casella G, Pavesi PC, Di Niro M, Medda M, Rubboli A, Lezha M, Sangiorgio P, Bracchetti D. G Ital Cardiol. 1996 Dec;26(12):1401-13.
  207. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. Rubboli A, Sobotka PA, Euler DE. Am J Physiol. 1994 Sep;267(3 Pt 2):H1054-61. doi: 10.1152/ajpheart.1994.267.3.H1054.
  208. [Relations between acute myocardial edema, coronary vascular resistance and left ventricular mechanics in isolated rat heart]. Rubboli A, Sobotka PA, Euler DE. Cardiologia. 1994 Jul;39(7):497-505.
  209. Efficacy of long-term administration of transdermal nitroglycerin in asymptomatic patients with effort-induced silent myocardial ischemia. Rubboli A, Sangiorgio P, Pavesi PC, Casella G, Mezzetti M, Bracchetti D. Cardiology. 1994;84(4-5):247-54. doi: 10.1159/000176407.
  210. Exercise-induced ventricular arrhythmias in patients with healed myocardial infarction. Casella G, Pavesi PC, Sangiorgio P, Rubboli A, Bracchetti D. Int J Cardiol. 1993 Jul 15;40(3):229-35. doi: 10.1016/0167-5273(93)90005-2.
  211. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, Gasbarrini G. J Hepatol. 1991 Mar;12(2):207-16. doi: 10.1016/0168-8278(91)90940-d.
  212. Felodipine in chronic stable angina: a randomized, double-blind, placebo-controlled, crossover study. Sangiorgio P, Di Pasquale G, Savonitto S, Urbinati S, Rubboli A, Cavallotti G, Pinelli G, Bracchetti D. Eur Heart J. 1990 Nov;11(11):1011-7. doi: 10.1093/oxfordjournals.eurheartj.a059628.
  213. [Gallopamil in stable effort angina. Effects of 2 different dosages]. Sangiorgio P, Rubboli A, Brunelli D, Bracchetti D. G Ital Cardiol. 1989 Jan;19(1):40-5.
  214. [Calcium antagonists in angina pectoris]. [https://pubmed.ncbi.nlm.nih.gov/3248701/] Bracchetti D, Sangiorgio P, Fulvi M, Rubboli A. G Ital Cardiol. 1988 Nov;18(11):970-3.

Ultimi avvisi

Al momento non sono presenti avvisi.

RSS